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Abstract
The diagnosis of diseases of the brain is based on additional methods, confirming the 
clinical diagnosis. One of the most objective methods is magnetic resonance imaging 
(MRI). A detailed quantitative evaluation became possible after the introduction of MRI 
voxel‐morphometry–statistical analysis of structural MRI images using a computerized 
segmentation matter of the brain gray and white matter. The decrease in the volume of 
the brain, as a manifestation of cerebral atrophy, is a common feature of many neurologi‐
cal diseases. We performed a study of brain structures in multiple sclerosis, Parkinson’s 
disease, and cerebrovascular diseases. In patients with multiple sclerosis the correla‐
tion was found between the score on a scale of Expanded Disability Status Scale and the 
total thickness of the cerebral cortex. In our study of the brain in Parkinson’s disease, 
the amount of the substantia nigra was slightly lower than in the control. In patients 
with long‐following Parkinson’s disease, the volume of substantia nigra was significantly 
higher than in patients with early stage. The increased volume was determined by the 
accumulation of organic iron compounds as a sign of neurodegeneration.
Keywords: magnetic resonance imaging, voxel morphometry, brain, gray matter, white 
matter, neurodegeneration, multiple sclerosis, Parkinson’s disease
1. Introduction
The human brain is the most important organ that controls the functions of all the other 
organs in the human body through neuronal connectivity and neuronal signal transmission. 
Central nervous system (CNS) is the most complex but a very poorly understood structure in 
the human body. The diagnosis of many diseases of the brain is based on additional research 
methods, confirming the clinical diagnosis. One of the most objective and intuitive methods 
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is magnetic resonance imaging (MRI). The technology to image the structure and function of 
the brain noninvasively (MRI, other methods of neuroimaging) has transformed our under‐
standing of neurological disorders, opening new approaches to treatment and prevention. 
For a long time, MRI was based on a visual qualitative analysis of the obtained images. The 
development of the method led to the emergence of different modes of research, there are 
fundamentally new methods—diffusion‐weighted image, the tensor image, perfusion MRI, 
functional MRI, and a method of MRI spectroscopy. However, these methods are mostly 
qualitative.
Neuroimaging may be divided into structural neuroimaging, which evaluates anatomic 
changes that occur in neurodegenerative conditions, and functional neuroimaging, which 
evaluates CNS activities such as blood flow and metabolism. For example, structural neu‐
roimaging with computed tomography (CT) and magnetic resonance imaging (MRI) has 
defined patterns and rates of brain volume loss in neurodegeneration. Moreover, structural 
neuroimaging may detect treatable conditions that may present with dementia‐like symp‐
toms. Functional neuroimaging with MRI (fMRI), single photon emission CT (SPECT), and 
positron emission tomography (PET) have greatly assisted in the understanding of blood 
flow, metabolism, and amyloid deposition. Application of MR spectroscopy (MRS) has also 
yielded novel information about neurodegeneration [1, 2].
A detailed quantitative evaluation became possible after the introduction of MRI voxel‐mor‐
phometry–statistical analysis of structural MRI images using a computerized segmentation 
matter of the brain GM and WM. Data about this technique were first published in 2000 [3]. 
MRI voxel morphometry requires the processing of data obtained by MRI study in the mode 
of the T1‐weighted images (WI) with a slice thickness of 1 mm.
Voxel morphometry is based on the calculation of local differences in brain tissue after level‐
ing expressed differences in anatomical structure and spatial position. This is achieved by spa‐
tial normalization (registration) of structural images into a single stereotactic space,  further 
segmentation of gray and white matter, cortical rectification of furrows and convolutions, and 
statistical analysis to detect differences between the experimental groups. By segmentation, 
we can separate the major cerebral and extracerebral structures (GM, WM, and cerebrospinal 
fluid, CSF), also using voxel morphometry, we can reveal focal anatomic lesions [4, 5].
The decrease in the volume of the brain, as a manifestation of cerebral atrophy, is a common 
feature of many neurological diseases. There is the general (total) and regional (local) atro‐
phy. Under the general atrophy, we can understand the volume reduction of brain paren‐
chyma and the increase of subarachnoid spaces and ventricles of the brain. The decrease in 
the volume of certain brain structures is called regional atrophy. In brain tissue, the atrophy 
is accompanied by loss of neurons and connections between them that allows to consider it as 
one of the markers of the severity of the disease.
There are two basic methods of studying the volumes of the brain: using separation of gray 
and white matter manually or using special computer programs. Both methods have both 
positive and negative sides. We have tested both approaches. We performed a study of brain 
structures in multiple sclerosis, Parkinson’s disease, and cerebrovascular diseases (CVD).
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2. Morphometry of the brain in multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS affecting 
more than 2 million people worldwide and leading to chronic progressive disability in the 
majority of cases. MS is heterogeneous both clinically and histopathologically, suggesting 
that different effector cells and molecular mechanisms are involved in the induction of tis‐
sue destruction. The most common form of MS, known as relapsing–remitting MS (RRMS), 
is associated with acute inflammatory episodes that reduce neurological function. RRMS 
patients may experience some recovery between relapses, but in 80% of cases, the disease 
evolves to a more progressive form with neurodegeneration termed secondary progressive 
MS (SPMS). The latter is associated with a gradual loss of neurological functions and is less 
dependent on inflammation [6–8]. Currently, it is generally assumed that immune, inflamma‐
tory, and neurodegenerative mechanisms involve in the pathogenesis of MS; it is a balance 
between the activity of inflammation, progressive degeneration, and reparative mechanisms 
and determines the clinical manifestations at each stage.
The main method of diagnosis in MS is magnetic resonance imaging (MRI). Standard tech‐
niques MRI is essential to confirm the nature determination of the activity of the pathological 
process and monitoring of the disease. Now, we use modern methods of MRI, which aims at 
clarifying the pathogenesis and pathophysiological mechanisms of formation of neurological 
deficit, the development of effective prognostic criteria, and new markers for the monitoring 
of the flow of inflammatory and neurodegenerative, atrophic component [9–11].
Initially, the presence of atrophy of the brain in MS patients was identified qualitatively, 
describing the extension of the ventricles and subarachnoid spaces and reducing the amount 
of substance of a brain. The next step was the quantitative assessment of atrophy of the brain 
with no differentiation of GM and WM. Currently, studies use different methods of MRI to 
assess how the global (brain in general) and regional atrophy. One of the most commonly 
used methods is to estimate the fraction of the brain parenchyma (BPF), which is determined 
by the ratio of the brain to the amount of the substance of the brain and cerebrospinal fluid 
(CSF). It is believed that in patients with MS, the regional atrophy may serve as a more sensi‐
tive marker of the severity of the disease than the general atrophy, but the results obtained 
in different studies often directly contradict each other. In recent years, it has been suggested 
that atrophy of cortical and subcortical gray matter prevails over the decrease in the volume 
of the white matter of the brain and largely determines the degree of disability of MS patients. 
Many researchers have noted that different types of MS course are characterized by their pat‐
terns of atrophy [12].
First, when an MS that the key importance was given to inflammatory demyelination of the 
WM and therefore considered that it undergoes atrophy. However, damage to axons within 
the WM lesions lead to atrophy, which was most likely evolving in two ways: the loss of 
substance in the demyelination and further Wallerian degeneration pathways associated with 
the lesion. WM atrophy affected certain areas of the brain, including both hemispheres of 
the brain, the brain stem, and the cerebellum. In patients with relapsing‐remitting multiple 
sclerosis (RRMS) compared with the control group, most pronounced atrophy of almost all 
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parts of the WM: the corpus callosum, cingulate gyri on both sides, certain divisions of the 
frontal lobes (including the upper sections of the radiate crown and the upper longitudinal 
beams), and temporal and occipital lobes (arch, upper and lower longitudinal beams, inferior 
frontal‐occipital tracts [13, 14].
Atrophy of the brain in MS is the result of a comprehensive process of demyelination, axo‐
nal degeneration, and neuronal death [15]. In the treatment of MS, special attention is paid 
to the prevention of neurodegenerative component, and recently, several studies have been 
conducted for the evaluation of drugs. It was discovered that the degree of disability of the 
patients is determined with a therapeutic effect on a neurodegenerative component of the 
disease. However, the relationship is ambiguous. After the usage of MS‐modifying drugs, 
there is a decrease in the degree of atrophy of the brain in the first year, then the physician can 
see the stabilization of process [16]. Thus, it may be the gradual, progressive atrophy of brain 
substance in MS but may be the fluctuations of its volume. In particular, acute inflammation 
with swelling of the brain tissue and the formation of new lesions during exacerbation of MS 
leads to a temporary increase in the volume of the brain and vice versa—glucocorticoid treat‐
ment leads to a temporary reduction of brain tissue—the so‐called pseudoatrophy [17]. As 
suggested, this is the result of reducing inflammation and swelling in the brain.
Some studies have shown that WM atrophy is less prominent compared to GM atrophy due 
to more pronounced inflammatory processes that can mask atrophy [18, 19]. It is believed that 
patients with MS regional atrophy may serve as a more sensitive marker of the severity of 
the disease than the general, but the results obtained in different studies are mixed and often 
directly contradict each other. In recent years, it has been suggested that atrophy of cortical 
and subcortical GM prevails over the decrease in the volume of WM in the brain. It predomi‐
nantly determines the degree of disability in patients with MS. However, many researchers 
note that different types of MS have the specific patterns of atrophy.
When analyzing the state of the GM in MS, it has been discovered that atrophy of the thala‐
mus develops earlier than the atrophy of the cortex, which was demonstrated in a study of 
patients with RRMS and secondary progressive multiple sclerosis (SPMS) during follow‐up 
[20, 21]. Atrophy of the thalamus observed in all types of MS course, to the greatest extent in 
SPMS, which is probably related to disease duration
The correlation was found between the score on a scale of Expanded Disability Status Scale 
(EDSS) and the total thickness of the cerebral cortex, precentral cortex, postcentral, parahip‐
pocampal, occipital gyri, and the caudate nucleus volume and a striped body. Some studies 
show that patients with sustained progression of disability by EDSS have a much higher rate 
of atrophic processes in comparison with patients with stable neurological symptoms. It is 
also believed that the amount of GM compared with WM volume is a more sensitive predictor 
of disability, measured by EDSS [22].
Cognitive impairment, including loss of memory, attention, and speed of information repro‐
duction, has been reported in 70% of patients with MS, and they occur already at early stages 
of the disease (within the first 3 years). Patients with RRMS with cognitive impairment com‐
pared with patients without such revealed a decrease in volume of the brain in general and 
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GM of the cerebral cortex. Indeed, cortical atrophy is predictive of cognitive impairments 
because even mild cognitive changes are associated with significant thinning of the cerebral 
cortex. Also, a significant correlation was discovered with atrophy of the thalamus [23].
Thus, the modern MRI techniques, including MRI voxel‐morphometry, significantly expand 
our understanding of the pathogenesis of MS. Numerous studies show that in addition to the 
WM atrophy, the GM atrophy in MS is already found in the early stages of the disease, and it 
progresses faster in healthy people, being a significant MRI predictor of the development of 
disability. Studies that show atrophy in different areas of the brain at the different types of MS 
course bring new contributions to the understanding of the pathophysiological mechanisms 
of the degenerative process. Now, we only accumulate our own data on the morphometry of 
the brain in MS.
We studied 10 patients with RRMS, five women, and five men. The diagnosis was based on 
McDonald criteria, 2010 revision. The age of the patients was from 24 to 36 years (average 
age/here and further data are given in the format M ± m/30, 7 ± 1, 22 years. At the time of the 
study, the disease duration ranged from 1 to 24 years (mean age of 8.1 ± 2.25 years). During 
follow‐up, only three patients had one to three exacerbations. Before therapy with drugs 
modifying the course of the disease, mild disability (EDSS ≤ 3.0) was in eight patients, moder‐
ate (EDSS 3.5–5.5 points)—in two, and no severe disability (EDSS ≥ 6.0 points) were observed. 
The average EDSS score before the start of the specific therapy was 2.5 ± 0, 25, during an exac‐
erbation—3.5 ± 0.34. All patients had no therapy before inclusion in the study. Therapy with 
glatiramer acetate (in a standard dose of 20 mg subcutaneously daily) was prescribed to three 
patients, but in the future, one of them was transferred to natalizumab therapy (in a stan‐
dard dose of 300 mg infusion monthly) in the cause of aggressive course of the disease (three 
exacerbations). Seven patients had therapy with interferon beta 1‐b in a dose of 9.6‐million 
IU subcutaneously through the day. The control group (CONTROL) consisted of 10 healthy 
individuals, five men and five women, mean age of 21.3 ± 1.9 years.
To assess the condition of patients, we used the standard neurological examination, Expanded 
Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC) which 
includes the quantitative tests that assess lower limb function/walking (Timed 25‐Foot Walk) 
and upper limbs (9‐Hole Peg Test), hearing test on addition of a sequence of digits PASAT‐3 
(Paced Auditory Serial Addition Test), and several subtests of the Wechsler Adult Intelligence 
Scale: subtest “Resemblance,” subtest “Digit span”, subtest “Coding”, subtest “Kohs Block 
Design Test “, Beck’s depression scale, and Beck’s anxiety scale.
Brain MRI was performed on “Initial Achieva 3.0 T” (Philips Medical System Nederland BV) 
with a magnetic field of 3 T. The study protocol included the use of T1‐WI with slice thickness 
1 mm, the distance between the slices–0 mm, and after contrast enhancement. The MRI was 
performed with the processing of the sequences for morphometry of anatomical MRI using 
FreeSurfer 5.3 (an open source software suite for processing and analyzing human brain MRI 
images) for segmentation and visualization of brain structures.
The results of voxel‐based morphometry using the anatomical MRI T1‐WI of the brain show 
a significant decrease in the cortical and subcortical GM volumes and WM in comparison to 
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CONTROL (Table 1). The volume of cortical GM in MS patients was 13.9% lower, while sub‐
cortical GM was 21.8%. The decline in GM of the thalamus was the highest—25.6%. The vol‐
ume of WM was lower than in the CONTROL by 20.4%, and the greatest difference was found 
in relation to the corpus callosum—46.6%. At the same time, it was discovered an increase in 
the volume of the third ventricle by 31.9% and the lateral ventricles by 84.4%. It was indicated 
that the severity of reduction in volumetric parameters of the brain increased in proportion 
to the duration of MS.
It was not found a clear relationship between the level of reduction in GM and WM volume of 
the brain and EDSS. But there was a positive relationship between the amount of Hypo lesions 
in the white matter of the brain and EDSS. We discovered that the parameters of neuropsycho‐
logical testing in patients with MS was worse than in CONTROL, and at exacerbation period, 
there was marked a more significant decline. We identified a probable correlation between 
reduced volumetric and neuropsychological parameters.
3. Morphometry of the brain in Parkinson’s disease
Parkinson’s disease (PD) is currently the most common among neurodegenerative diseases, 
its incidence is 200–300 cases per 100 thousand people. In Russia, according to epidemio‐
logical studies in some regions, the prevalence of PD is only 40–140 cases per 100 thousand 
population, which is considerably lower than in Western Europe and North America. The 
pathogenesis of PD is of great importance to the accumulation of intracellular inclusions (Levi 
Parameters (mm3) CONTROL MS
The total volume of cortical GM 521763.46 449010.5
The volume of subcortical GM1v 63915.5 50008.38
The total GM volume 696492.4 607442.001
The total volume of WM 503950.6 401106.7975
The volume of the lateral ventricles 14853.5 27396.225
Volume III ventricle 1221.7 1610.95
Volume IV ventricle 1764.6 1970.5
The volume of the cerebellum 158134.7 135249.45
The volume of the thalami 16330.5 12157.15
The hippocampal volume 10146.9 7818.45
The volume of the corpus callosum 3261.9 1740.55
The volume of hypointensive lesions in brain WM 899 8915.1
The volume of hypointensive lesions in brain GM 9.6 33.75
Table 1. The volume of the brain by MRI in patients with MS and CONTROL obtained by voxel morphometry (own 
data).
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bodies) in the neurons located in the compact part of the substantia nigra (SN), reflecting 
progressive neurodegeneration. Motor symptoms of PD are manifested at the stage when it 
is killed not less than 50% of dopaminergic neurons of the SN, and the typical picture of the 
disease is fully formed during the destruction of 80% of the cells [24].
Due to the decrease in the number of neurons of the SN, the number of dopaminergic pro‐
jections at the rear parts of the putamen is reduced that leads to the development of a triad 
of characteristic motor symptoms of PD—static tremor, bradykinesia, and rigidity, which is 
deployed in the next stages of the disease with postural instability. In the early stages of PD, 
not all symptoms are expressed equally; therefore, there are difficulties of differential diag‐
nostics of PD and symptomatic parkinsonism, torsion dystonia, and essential tremor that are 
not associated with degeneration of nigral neurons and a deficit of dopamine in the striatum, 
while in 15% of cases, the diagnosis of PD is wrong [25–28]. The complexity of differential 
diagnosis and, to some extent, delayed the debut of the classic clinical symptoms leading to 
late diagnosis of the neurodegenerative process and the low efficiency of symptomatic treat‐
ment, while the possibilities for pathogenetic help have been lost.
At this time, the researchers are studying actively the predictive value of various non‐motor 
symptoms that occur in the early stages of PD, as these symptoms of neurodegeneration man‐
ifest long before the development of the classic triad of motor symptoms. Known early signs 
of violations of smell, changes in the regulation of cardiac activity, disorders of motility of 
the gastrointestinal tract, ultrasound signs of early degeneration, disaster, and other changes, 
because they precede the manifestation of motor symptoms of PD in the years.
As a result of improving traditional methods of functional neuroimaging, the studies have 
been aimed at identifying qualitative and quantitative indicators of the morphology of the 
brain in PD. In this connection, the special interest is the study of dopaminergic structures of 
the brain stem. Despite the fact that currently there are data from multiple studies, obtained 
facts are rather contradictory. The difference in the results of volumetric studies of the SN in 
PD could be attributed to the difficulty of identifying the boundaries between the compact 
and reticular parts of the SN, lack of opportunity of contrasting these structures, individual 
differences in the volume of the midbrain and medulla in general [28, 29].
Using diffusion tensor MRI Tessa et al. [30] revealed the signs of a diffuse reduction in the 
volume of gray matter of the cerebral hemispheres in patients with newly diagnosed PD who 
did not receive specific therapy. These data are consistent with the hypothesis of PD stages of 
Braak [25], claiming that at the time of the manifestation of motor symptoms process of neu‐
rodegeneration is already becoming common. The authors found differences in the severity of 
atrophy with a predominance of rigidity or tremor obtained by using sophisticated statistical 
techniques, however, do not seem convincing. Some researchers using this technique revealed 
changes in the thalamus, SN, and its ascending and descending pathways in PD [31–33].
T1‐, T2‐, and T2*‐WI were used previously to study the anatomy of the midbrain, it is assumed 
that T1‐WI better reflects the lower divisions, however, none of the modes did not allow to 
distinguish the compact and reticular parts of CHS [34, 35]. Routine T1‐ and T2‐WI MRI do 
not reveal accurate structural changes in the SN in PD, which confirms its idiopathic nature. 
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Morphometric studies, using voxel morphometry obtained by different researchers, are con‐
tradictory, probably due to the difficulty of tracing the boundaries of the compact part of SN.
The contrast ratio of the SN is determined by the accumulation in it neuromelanin, ferritin and 
other iron substances, whose concentration is changed by natural aging, so in PD and other 
neurodegenerations. Reticular part of SN contains more iron than its compact part, which is 
manifested by hypotensivity of this area due to the decrease of the relaxation time T2. The 
compact part of SN contains more neuromelanin, and the iron atoms in them are in the bound 
state with the ferritin [36, 37].
Oikawa et al. [38] did not note significant changes of size and density of CHS in studies in 
modes T2 and proton density. Minati et al. [39] using the T1 with the suppression of the signal 
from gray and white matter in PD revealed hypointensity signal from the external part of the 
SN, mainly the reticular part of it. The authors in the study of SN at the level of the chiasm 
above the upper legs of the cerebellum said that there is significantly smaller area in patients 
with PD (72.2 ± 27.4 mm2) than in healthy individuals at similar (88.8 ± 28.7 mm2) or young age 
(of 91.8 ± 29.4 per mm2). The authors have not performed the volumetric study.
We carried out the clinical and neuroimaging examination of 4 groups of patients: 10 patients 
with the initial manifestations of PD, stage 1 on Hoehn and Yahr scale (PD1) [40], 10 patients 
with severe clinical manifestations, stage 3 on Hoehn and Yahr scale (PD2), 10 patients with 
early manifestations of CVD, after a transient ischemic attack (TIA) or minor/lacunar stroke 
with complete or almost complete regression of neurological deficits (CVD1), and 10 patients 
with severe manifestations of CVD after suffering repeated small/lacunar stroke (CVD2). The 
diagnosis of PD was established in accordance with generally accepted criteria of brain Bank 
of the UK PD society [41]. Control group (CONTROL) consisted of 10 apparently healthy 
persons aged 21–48 years.
MRI study was conducted on “Initial Achieva 3.0 T” (Philips Medical System Nederland BV) with 
a magnetic field of 3 T. The study protocol included the use of T2‐ and T2*‐weighted images (T2‐
Wi, T2*‐WI) using pulse sequences TSE (Turbo spin echo), FFE (Fast field echo), GraSE (Gradient 
spin echo). The orientation of slices was conducted nearly to the axial plane, parallel to the line 
connecting the middle of the chiasm and the lower contour of the corpus callosum  splenium. To 
explore dopaminergic structures of the brain stem, the middle block of the scanned sections was 
located between the upper and lower hillocks of the corpora quadrigemina. Also, we carried out 
the scanning in the coronal and axial planes, perpendicular to the main axial plane.
Regional assessment of the volume of brain matter of cerebral hemispheres and the CSF, GM, 
and WM of the midbrain were performed by the volumetric morphometry. For the region of 
the cerebral hemispheres, we used axial slices extending above the cavity of the third ven‐
tricle, through the bodies of the lateral ventricles, above the insula. After visual determination 
of the zone of interest, we performed automatic segmentation on the GM + WM and CSF.
To determine the volumetric characteristics of SN, we investigated sections of the midbrain in 
T2‐WI and FLAIR. T2 and T2* relaxation time changes as a result of the accumulation of iron 
in the area of SN in PD patients (Figure 1). The highest contrast of images we obtained in the 
FLAIR MRI. Study of SN included in its entirety as Hypo‐region compared to the white matter 
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of the midbrain. The normalization of the size SN on the volume of the midbrain did not per‐
form. For accurate tracing of the boundaries of SN and the nucleus ruber (NR), we used schemes 
Duvernoy’s Atlas of the Human Brain Stem and Cerebellum [42].
The boundaries of SN and NR were traced manually. The border was carried out by the 
regions, having approximately the intermediate brightness signal between SN and surround‐
ing white matter. To reduce the subjective factor, the study was conducted by two experts 
independently from each other.
A significant decrease in the brain volume compared to the CONTROL was observed only in 
the groups CVD1 and CVD2, while the increase in the volume of subarachnoid spaces was 
observed in all patients. The PD1 group showed a trend toward increasing the share of space 
filled with CSF in the preservation compared to the normal shares of the brain tissue. Patients 
of the PD2 group, along with the increase in the share of space filled with CSF, showed a trend 
toward a decrease of the relative volume of brain matter. The greatest reduction in the volume 
of brain matter with a corresponding increase space filled with CSF was observed in the CVD2 
group. The difference was statistically significant with the PD1 and PD2 groups (Table 2).
We carried out morphometry of SN in PD [43]. Although the amount of SN in PD1 patients was 
slightly lower than in the CONTROL, but the difference was not significant. At the same time 
in PD2 patients, the volume of SN was significantly higher than in PD1 patients (Figure 2). It 
should be emphasized that the indicators include both compact and reticular part of SN, and 
hypotensive of this zone was determined by the accumulation neuromelanin, ferritin, and 
Figure 1. Images of the midbrain from the ponto‐mesencephalic (1) to mesencephalic‐diencephalic transition (9) on 
T2‐WI (slice thickness 2 mm, the distance between the slices–0 mm). In Sections 3–8 visualized SN, in Sections 5–9—NR, 
slice 9–the subthalamic nucleus (arrow) positioned as a continuation of SN at the diencephalic level (own data).
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other organic iron compounds. Previously, researchers revealed hyperechogenicity of the SN 
in patients with PD in transcranial ultrasonography. Obviously, in this case, MRI revealed a 
phenomenon similar to ultrasonography.
Thus, MRI neuroimaging of dopaminergic structures of the brain stem is feasible, it can detect 
volumetric changes reflecting a neurodegenerative process. Although the positron emission 
tomography allows to obtain more information regarding the functional state of the dopa‐
minergic structures in PD; however, this method remains inaccessible. Therefore, voxel mor‐
phometry of SN is a useful method of diagnosis and monitoring of PD patients.
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Figure 2. Volume of SN according to the results of morphometry axial slices (in mm3) in the T2‐Wi and FLAIR in PD1, 
PD2, and CONTROL. The horizontal line indicates the median in each group (own data).
Group Volume of brain matter Volume of the lateral ventricles Volume of the subarachnoid space
PD1 0.85 ± 0.01 0.04 ± 0.003 A 0.11 ± 0.01 A
PD2 0.82 ± 0.01 A 0.06 ± 0.01 B 0.12 ± 0.01 A
CVD1 0.81 ± 0.01 A, B 0.07 ± 0.004 B 0.12 ± 0.01 A
CVD2 0.78 ± 0.01 A, B, C 0.09 ± 0.01 A, B, C 0.12 ± 0.01 A
CONTROL 0.87 ± 0.01 0.06 ± 0.01 0.07 ± 0.01
Abbreviations: A, p < 0.01 value is calculated against CONTROL; B, p < 0.01 value is calculated against PD1; C, p < 0.05 
value is calculated against PD2 by volume of the brain and p < 0.01 for the volume of the lateral ventricles.
Table 2. The ratio of the volumes of brain matter and spaces filled with CSF, in patients with PD, CVD, and control group 
(M ± m) (own data).
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